The U.S. Food and Drug Administration today granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. First PD-1 blocking drug to receive agency...
Event Date/Time 09/06/2014 Topic Annual Membership Conference Description TxSCO Annual Membership Conference Location Éilan Hotel 7103 La Cantera Parkway San Antonio TX, 78256 RSVP Required No Fees Special room rate of $189 (Expires August 14, 2014) Call 855-257-3040...
ASH Launches New Drug Access Webpage As part of ASH’s effort to ensure patient access to safe and effective hematologic drugs that are expensive and often in specialty tiers, ASH launched a new webpage: www.hematology.org/Clinicians/Drugs/Programs that provides...
On August 14, 2014, the U. S. Food and Drug Administration approved bevacizumab solution for intravenous infusion (Avastin, Genentech, Inc.) for the treatment of persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or...
